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Abstract 
 
The primary role of pyruvate dehydrogenase kinase (PDK) is to regulate the activity of 
pyruvate dehydrogenase complex (PDC) with respect to the metabolic clearance of 
glucose via a phosphorylation mechanism.  Therefore, inhibition of PDK is predicted to 
be important in the treatment of diabetes.  ADP binds to the active site of PDK; and has 
been shown to inhibit PDK activity.  This research work was aimed at studying one of the 
isoforms of PDK, specifically the rodent form, PDK4 (rPDK4) and further elucidating the 
binding properties of ADP to rPDK4.   
 
The hypothetical structure of rPDK4 was modelled based on the coordinates of the 
published rPDK2 structure.  The overall structural topology of rPDK2 appears to be 
preserved in rPDK4.  Further, the ADP binding site between rPDK2 and rPDK4 was 
conserved at both the primary and tertiary level, and this suggested the mechanism of 
ADP binding to rPDK2 would be similar to that of rPDK4.   
 
A histidine tagged-rPDK4 protein was expressed and purified using affinity and gel 
filtration chromatography.  It was determined to be a homodimer (97 kDa) comprising 
two identical subunits.  The rPDK4 protein was further identified to be rPDK4 using 
Western blot analysis as it reacted positively with an anti-rPDK4 monoclonal antibody.  
The purified rPDK4 protein contained kinase activity since it was able to undergo 
autophosphorylation and subsequently phosphorylate a peptide that contained the E1α 
subunit sites that are known to be phosphorylated by PDKs.  The structure of rPDK4 
protein was also characterised using circular dichroism and fluorescence spectroscopy.  
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The spectroscopic data of rPDK4 was consistent with published data on the structure of 
rPDK4. 
 
The binding of ADP and ATP was studied using fluorescence quenching as both these 
ligands quench the intrinsic tryptophan fluorescence of rPDK4.  The dissociation constant 
(Kd) values for ADP and ATP were determined to be 37 and 17.4 µM, respectively.  The 
moderate affinity binding of ATP will greatly favour the exchange of ADP for a molecule 
of ATP to prevent PDK inhibition by ADP.   
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1 Introduction 
 
1.1 Diabetes mellitus 
 
Type 2 diabetes mellitus (non-insulin dependent diabetes mellitus; T2DM) affects 6 % of 
the modern society and this statistic is expected to grow annually by 6 % world wide 
(Korc, 2003; Kopelman and Hitman, 1998; Amos et al., 1997).  Diabetes results from the 
lack of synthesis of insulin, whose primary biological function is to regulate and maintain 
glucose homeostasis.  Insulin resistance and obesity have been reported as risk factors for 
the development of T2DM (Kahn and Flier, 2000).  During insulin resistance, cells 
involved in glucose metabolism such as adipose tissue, skeletal muscle and liver, are 
unable to respond to insulin signalling, thus resulting in high glucose levels in the blood.  
 
1.2 Glucose regulation 
 
Glucose is obtained from dietary carbohydrate and gluconeogenesis and its level in the 
body is tightly regulated.  Gluconeogenesis primarily occurs in the liver and to a lesser 
extent in the kidney (Coleman et al., 1992).  During gluconeogenesis, glucose is 
synthesised from non-carbohydrate precursors (pyruvate, lactate and glucogenic amino 
acids) as well as the breakdown of glycogen.  Glycolysis ensures that the glucose is 
cleared from the blood and utilized as energy.  Insulin is the primary hormone that 
mediates glucose clearance (Hawkes and Kar, 2002).  Insulin binds to its receptor and 
induces a signalling cascade (Whitehead et al., 2000) that results in the transportation of 
glucose into the cell by glucose transporter protein (Glut4) (Zierath et al., 1996), as well 
as activation of enzymes that are involved in the glycolytic pathway and suppression of 
 2 
gluconeogenesis.  Under normal physiological conditions, glucose is metabolised to 
pyruvate in the cytosol.  Pyruvate is then transported by pyruvate binding protein into 
mitochondria where it is metabolised into acetyl-CoA (Figure 1).  The acetyl-CoA can be 
used in fatty acid synthesis in the cytosol or directly fed into the TCA cycle in the 
mitochondria (Randle, 1986 and Figure 1).   
 
 
 
 
 
Figure 1: Schematic diagram showing the role of PDC in the clearance of glucose. 
The link between glucose metabolism (in the cytosol), the TCA cycle (mitochondrion), and lipid synthesis 
cytosol is shown.  The reaction catalysed by PDC is also shown. The positive regulator of PDC (pyruvate 
dehydrogenase phosphatase, PDP) is shown on the left, and the negative regulator (pyruvate dehydrogenase 
kinase, PDK) is shown on the right (Adapted from Patel and Korochkina, 2001). 
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1.3 Role of pyruvate dehydrogenase complex in glucose metabolism  
 
The conversion of pyruvate to acetyl-CoA is irreversible and is catalysed by the pyruvate 
dehydrogenase complex (PDC), which is located in the matrix of mitochondria (Randle, 
1986).  PDC plays an important role in dictating the rate at which carbohydrate-derived 
substrates will be fully oxidized in tissues with large energy demands such as brain, 
muscle, heart and liver (Randle, 1986), thus contributing to the maintenance of glucose 
homeostasis (Randle, 1986; Patel and Roche, 1990).  Consistent with this observation, the 
activity of PDC has been reported to be low during conditions of reduced glucose 
metabolism such as obesity, starvation and diabetes (Wieland et al., 1971; Denyer et al., 
1981 and Henry et al., 1991).  
 
PDC is a multi-enzyme complex that is found in the mitochondria (Patel and Roche 1990; 
Reed et al., 1985).  It is composed of multiple copies of four different subunits (Patel and 
Roche 1990; Reed et al., 1985) that include three catalytic enzymes (pyruvate 
dehydrogenase (E1), Dihydrolipoamide acetyltransferase (E2), and Dihydrolipoamide 
dehydrogenase (E3)), two regulatory enzymes (pyruvate dehydrogenase kinase (PDK) 
and pyruvate dehydrogenase phosphatase (PDP)), and E3 binding protein (E3Bp) (Patel 
and Roche 1990).  E1 is made up of E1α and E1β subunits; the E1α has pyruvate 
dehydrogenase activity, and is responsible for the decarboxylation of pyruvate.  The E2 
subunit is responsible for the transfer of acetyl group to CoA while the E3 subunit 
transfers electrons to NAD+ forming NADH (Patel and Roche 1990).  
 
PDC catalyses the oxidative decarboxylation of pyruvate, and links glycolysis to the 
tricarboxylic acid cycle and ATP production (Figure 1).  The efficiency of PDC is crucial 
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in tissues with a high ATP requirement and in lipogenic tissue (providing acetyl CoA for 
fatty acid synthesis).  In an event where glucose is scarce, suppression of PDC is crucial.  
PDC is highly regulated due to the role that it plays in glucose homeostasis.   
 
1.4 Regulation of PDC 
 
PDC is regulated via both short-term and long-term mechanisms.  The regulation of PDC 
within a few minutes to hours is termed short-term regulation, while regulation that 
occurs at transcriptional level within days to weeks is long-term (Patel and Korotchkina, 
2001).  With respect to maintenance of glucose homeostasis especially during transition 
between the fed and fasted states, PDC regulation via the short-term mechanism is highly 
critical.  In the short-term mechanism, the E1 subunit of PDC is inactivated through 
phosphorylation by PDK, and reactivated via dephosphorylation by PDP (Yeaman et al., 
1978; Teague et al., 1979; Hucho et al., 1972 and Figure 2).  PDK phosphorylates the 
E1α subunit of PDC on serine residues that are located on three different sites.  These are 
designated site 1 (Ser264), site 2 (Ser271) and site 3 (Ser203) (Sale and Randle, 1981).  
Korochkina and Patel (1995) constructed E1α mutants by converting the serine residues 
at different phosphorylation sites to alanine, leaving only one functional phosphorylation 
site at a time.  They reported that phosphorylation of each site alone results in the 
complete inactivation of PDC (Yeaman et al., 1978; Dahl et al., 1987; Korotchkina and 
Patel, 1995).  These sites are believed to define PDK species specificity. 
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Figure 2: Regulation of PDC activity by a phosphorylation-dephosphorylation cycle. 
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isoforms towards the three phosphorylation sites of the E1 PDC subunit differ 
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highest activity towards site 2 when compared to the other isomers with PDK1, PDK2 
and PDK3 (Korotchkina and Patel, 2001, Kolobova et al., 2001).  The observation that 
the activation of PDC by PDP is much slower when site 2 is phosphorylated (Holness and 
Sugden, 1989) led to the hypothesis that the phosphorylation of site 2 is primarily for 
slowing down the rate of re-activation of PDC by PDP (Korotchkina and Patel, 2001).   
 
PDC activity is also regulated through a feed back loop.  For example, the products of 
PDC reaction (e.g. NADH and acetyl-CoA) inactivate PDC by increasing the activity of 
PDK (Cooper et al., 1975; Holness and Sugden, 1989).  PDC substrates (e.g., pyruvate 
and NAD+) activate PDC by inhibiting PDK activity.  This feedback loop is shown 
through schematics in Figure 1.  
 
1.5 Regulation of PDK 
 
As discussed above, PDK plays a critical role in glucose homeostasis by regulating PDC 
activity.  Consistent with this role, PDK activity is also tightly regulated through long-
term and short-term mechanisms (Siess and Wieland, 1976; Dennis et al., 1978; Kerbey 
and Randle, 1982).  
 
1.5.1 Long-term mechanism  
 
The long term regulation of PDK occurs at the gene expression level and is believed to be 
a part of an adaptive response to conditions of decreased glucose utilization, and 
increased fatty acid oxidation (Randle, 1986).  This state is induced by nutrition and 
hormonal changes (Wu et al., 1998).  For example, starvation (Wu et al., 1998; Kolobova 
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et al., 2001; Sugden et al., 1998), high fat feeding (Sugden et al., 2000; Holness et al., 
2000) and diabetes (Sugden et al., 1998; Holness et al., 2000; Wu et al., 1999) lead to 
high PDK4 expression.  Hormones, such as insulin, have also been shown to regulate 
PDK levels by suppressing PDK gene expression (Huang et al., 2000; Majer et al., 1998). 
Glucocorticoids are also known to induce PDK4 expression (Huang et al., 2000).  
However their mechanism of activation is not clearly understood. 
 
1.5.2  Short-term mechanism 
 
The short term regulation of PDK involves direct modification of its activity by the 
substrates (pyruvate, NAD+, and CoA) and the products (NADH, and Acetyl-CoA) of the 
PDC reaction (Figure 1 and Figure 3).  Pyruvate inhibits PDK activity by binding to an 
allosteric site on PDK (Pratt and Roche, 1979; Kato et al., 2005).  Furthermore, the effect 
of pyruvate to PDK is synergistic with the effect of ADP (Pratt and Roche, 1979).  It is 
believed that the binding of pyruvate to the PDK-ADP complex results in conformational 
changes which prevent release of the ADP molecule from the active site of PDK.  This 
ensures that the PDK remains in an inactive form (Kato et al., 2005; Steussy et al., 2001).  
NADH, and acetyl-CoA (Figure 1 and Figure 3) induce PDK activity (Ravidran et al., 
1996 and Bowker-Kinley et al., 1998) by binding to the inner lipoyl domain (L2) of PDC. 
 
1.6 Expression of PDK and its link to T2DM 
 
PDK isoforms are expressed differently in different cell types (Bower-Kinley et al, 1998; 
Bowker-Kinley and Popov, 1999).  The expression of PDK1 is limited to heart and 
pancreas (Bowker- Kinley and Popov, 1999; Sugden et al., 2001; Wu et al., 1999).  PDK 
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2 is expressed with low amounts in the lung and spleen (Huang et al., 1998), whereas 
PDK3 is found only in the testis, kidney and brain (Huang et al., 1998; Bowker-Kinley 
and Popov, 1999).  For example, the expression of PDK4 is found in the tissues that are 
important in the metabolic clearance of glucose such as liver and skeletal muscle 
(Bowker-Kinley and Popov, 1999; Sugden et al., 2001; Wu et al., 1999).  This suggests 
that PDK4 is the critical isomer involved in the maintenance of glucose homeostasis.  
Consistent with this hypothesis, PDK4 is expressed in high levels during obesity and 
diabetes (Holness and Sugden, 1989; Kolobova et al., 2001).  In addition, an increase in 
PDK4 expression has been observed in response to starvation and insulin resistance  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: The long-term and short-term regulation of PDK.   
The reaction catalysed by PDC is also shown.  The arrows show factors that induce PDK expression and 
activity. The broken lines indicate factors that inhibit PDK expression and activity. 
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Taking into account that PDK4 shows high specificity towards site 2 of PDC, the 
increase of PDK4 levels in response to starvation, insulin resistance and diabetes is 
believed to be important for site 2 phosphorylation.  It is postulated that phosphorylation 
of site 2 by PDK4 results in limiting the rate of PDP-dependent reactivation of PDC, thus 
ensuring that PDC remains in the inactive form.  This postulate is supported by the 
observation that the reactivation of PDC in the heart, liver and skeletal muscle is much 
slower under conditions of high PDK4 expression than under conditions of low PDK4 
expression (Holness and Sugden, 1989).  Therefore, PDK4 seems to be an ideal target for 
long-term inhibition of PDK activity with respect to control of T2DM. 
 
1.7 Classification of PDK  
 
PDKs, together with branched-chained α-ketoacid dehydrogenase kinases (BCKDK), 
form a novel family of eukaryotic protein kinases, namely the mitochondrial protein 
kinases (mPKs) (Popov et al., 1993; Davier et al., 1995).  These are serine specific 
protein kinases which share more similarity with prokaryotic protein kinases, despite 
being eukaryotic.  PDKs belong to the ATPase/kinase superfamily which consists of 
bacterial histidine kinases (EnzV and CheA) and ATPases (Hsp90 and DNA Gyrase B) 
(Harris et al., 1995), whereas eukaryotic protein kinases have a different molecular 
signature (Popov et al., 1993; Hanks and Hunter, 1995) that is depicted in Figure 4A.  
The catalytic subunit of eukaryotic serine/threonine kinases contains eight subdomains 
which play an essential role in the functioning of the enzyme through involvement in the 
binding and orientation of ATP, or the protein substrate.  They also partake in the transfer 
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of the γ-phosphate from ATP to the acceptor hydroxyl residue (Ser, Thr or Tyr) of the 
protein substrate (Hanks and Hunter, 1995).   
 
The PDK enzymes, despite being mammalian serine protein kinases, lack sequence 
motifs that are associated with eukaryotic serine/threonine kinases (Popov et al., 1993), 
but show more similarity to prokaryotic histidine kinases (Popov et al., 1993).  The 
structural elements of PDKs which are also characteristic of histidine kinases have been 
defined by a number of researchers (Popov et al., 1993; Steussy et al., 2001 and Kato et 
al., 2005).  These are depicted in Figure 4B. 
 
1.8 Structure of PDK 
 
Primary sequence analysis of the PDK isomers shows that they contain a poorly 
conserved N-terminal domain and a highly conserved C-terminal domain (Figure 4B and 
Figure 5).  Furthermore, PDK isomers exhibit high sequence similarity within the group 
(Figure 5).  PDK isoforms show high sequence conservation among different eukaryotic 
species, for example rat and human PDK2 proteins share greater than 95 % identity in 
their primary amino acid sequence.  The total number of amino acid residues varies 
among the different PDK isomers, for example PDK1 has 436 residues, PDK2 and PDK4 
have 407 residues, and PDK3 has 406 residues (Rowels et al., 1996; Figure 5). Similarly, 
the apparent molecular masses of the PDKs determined by polyacrylamide gel 
electrophoresis vary such that mature PDK1 corresponds to a 45 kDa subunit, whereas 
mature PDK2, PDK3, and PDK4 correspond to a 48 kDa subunit. 
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In the PDK family, PDK2 (Steussy et al., 2001) and PDK3 (Kato et al., 2005) are the 
only isomers with crystal structures that have been solved.  PDKs are reported to be 
homodimers (Figure 6A) with each monomer folding into a well defined 45 kDa subunit 
(Figure 6; Steussy et al., 2001; Kato et al., 2005).  
 
 
A 
 
 
B 
 
 
 
Figure 4: Comparison of the primary structure of eukaryotic serine/threonine 
kinases with that of the PDK family.  
Primary structures of ATPase/kinase superfamily and of eukaryotic serine/threonine kinase are shown in 
Figure 4A (Hanks and Hunter, 1995) and 4B (Popov et al., 1993), respectively.  The conserved subdomains 
which are the signature regions of these kinases are depicted in the figure above.  
 12 
 
PDK1            MRLARLLRGAALAGPGPGLRAAGFSRSFSSDSGSSPASERGVPGQVDFYARFSPSPLSMK 60 
PDK2            MRWFRALL--------------------------KNASLAGAPKYIEHFSKFSPSPLSMK 34 
PDK3            MRLFRWLL--------------------------KQP----VPKQIERYSRFSPSPLSIK 30 
PDK4            MRWFRALL--------------------------KNASLAGAPKYIEHFSKFSPSPLSMK 34 
                **  * *                           . .    .*  :: :::*******:* 
 
PDK1            QFLDFGSVNACEKTSFMFLRQELPVRLANIMKEISLLPDNLLRTPSVQLVQSWYIQSLQE 120 
PDK2            QFLDFGSSNACEKTSFTFLRQELPVRLANIMKEINLLPDRVLSTPSVQLVQSWYVQSLLD 94 
PDK3            QFLDFGRDNACEKTSYMFLRKELPVRLANTMREVNLLPDNLLNRPSVGLVQSWYMQSFLE 90 
PDK4            QFLDFGSSNACEKTSFTFLRQELPVRLANIMKEINLLPDRVLSTPSVQLVQSWYVQSLLD 94 
                ******  *******: ***:******** *:*:.****.:*  *** ******:**: : 
 
PDK1            LLDFKDKSAEDAKAIYDFTDTVIRIRNRHNDVIPTMAQGVIEYKESFGVDPVTSQNVQYF 180 
PDK2            IMEFLDKDPEDHRTLSQFTDALVTIRNRHNDVVPTMAQGVLEYKDTYGDDPVSNQNIQYF 154 
PDK3            LLEYENKSPEDPQVLDNFLQVLIKVRNRHNDVVPTMAQGVIEYKEKFGFDPFISTNIQYF 150 
PDK4            IMEFLDKDPEDHRTLSQFTDALVTIRNRHNDVVPTMAQGVLEYKDTYGDDPVSNQNIQYF 154 
                :::: :*..** :.: :* :.:: :*******:*******:***:.:* **. . *:*** 
 
PDK1            LDRFYMSRISIRMLLNQHSLLFGGKGKGSPSHRKHIGSINPNCNVLEVIKDGYENARRLC 240 
PDK2            LDRFYLSRISIRMLINQHTLIFDG--STNPAHPKHIGSIDPNCSVSDVVKDAYDMAKLLC 212 
PDK3            LDRFYTNRISFRMLINQHTLLFGG--DTNPVHPKHIGSIDPTCNVADVVKDAYETAKMLC 208 
PDK4            LDRFYLSRISIRMLINQHTLIFDG--STNPAHPKHIGSIDPNCSVSDVVKDAYDMAKLLC 212 
                ***** .***:***:***:*:*.*  . .* * ******:*.*.* :*:**.*: *: ** 
 
PDK1            DLYYINSPELELEELNAKSPGQPIQVVYVPSHLYHMVFELFKNAMRATMEHHANRGV-YP 299 
PDK2            DKYYMASPDLEIQEVNATNATQPIHMVYVPSHLYHMLFELFKNAMRATVESHESSLT-LP 271 
PDK3            EQYYLVAPELEVEEFNAKAPDKPIQVVYVPSHLFHMLFELFKNSMRATVELYEDRKEGYP 268 
PDK4            DKYYMASPDLEIQEVNATNATQPIHMVYVPSHLYHMLFELFKNAMRATVESHESSLT-LP 271 
                : **: :*:**::*.**. . :**::*******:**:******:****:* : .     * 
 
PDK1            PIQVHVTLGNEDLTVKMSDRGGGVPLRKIDRLFNYMYSTAPRPRVETSRAVPLAGFGYGL 359 
PDK2            PIKIMVALGEEDLSIKMSDRGGGVPLRKIERLFSYMYSTAPTPQPG-TGGTPLAGFGYGL 330 
PDK3            AVKTLVTLGKEDLSIKISDLGGGVPLRKIDRLFNYMYSTAPRPSLEPTRAAPLAGFGYGL 328 
PDK4            PIKIMVALGEEDLSIKMSDRGGGVPLRKIERLFSYMYSTAPTPQPG-TGGTPLAGFGYGL 330 
                .::  *:**:***::*:** *********:***.******* *    : ..********* 
 
PDK1            PISRLYAQYFQGDLKLYSLEGYGTDAVIYIKALSTDSIERLPVYNKAAWKHYNTNHEADD 419 
PDK2            PISRLYAKYFQGDLQLFSMEGFGTDAVIYLKALSTDSVERLPVYNKSAWRHYQTIQEAGD 390 
PDK3            PISRLYARYFQGDLKLYSMEGVGTDAVIYLKALSSESFERLPVFNKSAWRHYKTTPEADD 388 
PDK4            PISRLYAKYFQGDLQLFSMEGFGTDAVIYLKALSTDSVERLPVYNKSAWRHYQTIQEAGD 390 
                *******:******:*:*:** *******:****::*.*****:**:**:**:*  **.* 
 
PDK1            WCVPSREPKDMTTFRSA- 436 
PDK2            WCVPSTEPKNTSTYRVS- 407 
PDK3            WSNPSSEPRDASKYKAKQ 406 
PDK4            WCVPSTEPKNTSTYRVS- 407 
                *. ** **:: :.::    
 
Figure 5: Multiple alignment of amino acid sequences of the rat PDK isoforms.  
The sequences were aligned using ClustalW, version 1.83 (Thompson et al., 1994).  The sequence of the 
PDK isozymes were obtained from GenBank and their accession numbers are as follows: PDK1-Q15118, 
PDK2-Q64536, PDK3-Q15120, and PDK4- O54937.  Colours indicate chemical properties of the specified 
amino acid residues; asterisks at the bottom of each sequence alignment indicate residues that are 
conserved among the different PDK proteins; the colon indicates amino acid substitution with conserved 
hydrophobicity or chemical properties; full stop indicates position where there are at least two amino acid 
conservations.  Shaded regions indicate the subdomains that are conserved in the PDK family as well as 
bacterial histidine kinases.  These are labelled above each conserved box. 
  
G1-box G2-box 
 N-box 
H-box 
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Figure 6: A ribbon representation of the structure of rat PDK2. 
These images were generated using Swiss PDB Viewer (Guex and Peitsch, 1997) based on coordinates of 
1JM6 (PDB code) published by Steussy et al. (2001).  The dimer and monomer are shown in A and B, 
respectively.  α-Helices are coloured in red, β-strands are coloured in yellow, and the loop regions are 
coloured in pink.  In addition, the conserved subdomains are shown in the following colours: blue is G1 
box, G2 box is green, N box is cyan and H- box is lilac. 
A 
B 
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The C-terminal domain is an α/β structure with five β strands (Figure 6).  This fold 
resembles the one present in the ATPase/kinase superfamily such as CheA (Bilwes et al., 
1999), enzyme kinases (Tanaka et al., 1998) and Hsp90 (Prodromou et al., 1997). 
Furthermore, the C-terminal domain contains the three subdomains referred to as N- box 
(Glu-x-x-Lys-Asn-x-x-Ala), G1-box (Asp-x-Gly-x-Gly) and G2-box (Gly-x-Gly-x-Gly) 
(Popov et al., 1993; Steussy et al., 2001; Figure 5 and 6B).  These subdomains are 
present throughout the ATPase/kinase superfamily.   
 
The G-boxes contain glycine rich loops which are characteristic of nucleotide binding 
domains (Rossman et al., 1974).  Their nucleotide binding role was confirmed by 
resolving the structure of rat PDK2 that was crystallised with a bound molecule of ADP 
(Steussy et al., 2001).  The residues in the G1-box served as the basis of adenine specific 
interaction between ADP and the kinase.  The G1-box is part of a loop connecting α 
helices 10 and 11, and it forms one side of the binding pocket with the G2-box forming 
the other side (Steussy et al., 2001).  The G-boxes together with the N-box serves as a 
unique ATP binding fold (Bergerat et al., 1997 and Alex and Simon 1994) and an ATP 
lid (Machiuss et al., 2001 and Kato et al., 2005).  The amino acids in the N-box play an 
important role in the activity of PDK.  
 
The N-terminal domain is made up of eight α-helices connected by flexible loops and this 
domain begins at residue 1 and ends at residue 179.  The N-terminal domain contains a 
conserved subdomain called an H-box (x-Asn-x-His-x-Asp) (Figure 5; Kim and Forst, 
2001; Parkinson and Kofoid, 1992) which was initially predicted to be the site of 
autophosphorylation of PDK (Harris et al., 1995).  The α-helices form a four helix bundle 
that resembles the histidine phosphoryl-transfer (HPt) domain of the two-component 
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systems.  In a two-component signal transduction pathway, a histidine kinase catalyses 
the first step where the sensor domain responds to a signal by autophosphorylation of a 
histidine residue within the transmitter domain.  This is then relayed by transferring the 
phosphate group to an aspartic acid residue within the receiver domain of a cognate 
response regulator protein which is usually a transcription factor.  However, in PDKs, the 
H-Box in the N-terminal domain was proved not to be the site of PDK 
autophosphorylation, since autophosphorylation was mapped to serine residues in this 
domain (Thelen et al., 2000). 
 
1.9 Reaction mechanism of PDK  
 
At present, all studied and characterized histidine kinases transfer phosphate from an 
autophosphorylated histidine residue to an aspartate residue resulting in transduction of 
cellular signals.  PDK contains two prototypical component histidine motifs (Popov et 
al., 1993) and His115 was presumed to be a site of autophosphorylation and a phosphor-
His catalytic intermediate in PDKs.  Studies performed by Mooney and co-workers 
demonstrated that treatment of PDK by histidine modifying reagents diethyl 
pyrocarbonate and dichloro-(2,2':6',2'-terpyridine)-platinum (II) dihydrate completely 
abrogates PDK activity (Mooney et al., 2000).  This supported an essential role of His115 
in PDK catalytic activity.  This theory was later disproved by solving the crystal structure 
of rat PDK2 (Steussy et al., 2001).  The determination of the structure of rat PDK2 
suggested that His115 is solvent inaccessible making it unlikely to partake in a phosphor-
histidine intermediate.  Furthermore, His115 plays an important role in making a number 
of crucial structural hydrogen bonds (Steussy et al., 2001).  Currently, the site of 
autophosphorylation of PDK is not clearly defined. 
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In attempt to decipher the reaction mechanism of PDK, Tuganova et al. (2001) and 
Tovar-Mendez et al. (2005) studied the roles of Leu234 and Glu238 which are located in the 
N –box.  The mutation of these amino acid residues to alanine resulted in a complete loss 
of PDK activity.  The asparagine and lysine residues which are also located in the N-box 
were found to interact directly with ATP (Steussy et al., 2001).  According to the rPDK2 
structure, the lysine residue in the N-box is oriented towards the ATP binding site.  It was 
therefore hypothesised that this lysine residue is involved in the catalysis of PDK.  This 
hypothesis was strengthened by the low kcat of PDK mutated at this lysine residue (Tovar-
Mendez et al., 2005).   
 
Tovar-Mendez et al. (2005) proposed a model for the catalytic roles of amino acids in the 
N-box (Figure 7).  In this model, the conserved amino acids of the N-box (Glu and Lys) 
participate in binding of Mg2+ via a water molecule that coordinates the Mg2+ with 
asparagine completing the magnesium octahedral sphere.  The proposed role of Glu238 
was strengthened by observing that, in the other members of the ATPase/kinase 
superfamily such as CheA and topoisomerase, the amino acids that correspond to Glu238  
participate indirectly in the binding of Mg2+ via a water molecule that coordinates the 
Mg2+ (Bilwes et al., 2001; Corbett and Berger, 2003).  The base catalyst is proposed to be 
either located in the ATP lid or in the substrate.   
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Figure 7: Proposed model for the roles of the amino acids in the N-box. 
Dotted lines indicate the interaction between the amino acid residues and magnesium or water molecules.  
The water molecules bridge Mg2+ with Glu243 and Lys242.  The Asn242 is involved in the direct binding of 
Mg2+.  The two water molecules, Glu243, Lys242 and Asn242 complete the magnesium octahedral sphere 
(taken from Tovar-Mendez et al., 2005). 
 
 
1.10 Inhibitors of PDK 
PDK has received attention as a target for T2DM therapy due to its role in glucose 
metabolism and diabetes.  Therefore, there have been a number of efforts to identify or 
design PDK inhibitors.  Currently, the only known inhibitor of PDK that has reached 
clinical trial stage is Dichloroacetate (DCA).  Recently, other inhibitors of PDK activity 
such as triterpenes (Aicher et al., 1999), analogues of ATP, lactones and halogenated 
acetophane (Mann et al., 2000) have been identified (Figure 8).  However, they have not 
yet reached clinical trial stage.   
 18 
 
 
               
 
           
                            
 
 
  
 
Figure 8: Structures of PDK inhibitors.  
These structures were adapted from Mann et al. (2000).   
 
1.10.1 DCA as a PDK inhibitor 
 
DCA (Figure 8) is a non-hydrolysable analogue of pyruvate that has been shown to 
improve the diabetic condition (Whitehouse et al., 1974 and Stacpoole et al., 1979).  In 
Non-hydrolysable ATP analogue: adenosine5,-
[β,γ-imido] triphosphate (p[NH]ppA 
Sodium dichloroacetate 
Halogenated acetophane Triterpine 
Lactones 
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addition, DCA has been used for other conditions in which PDC activity is reduced such 
as ischemia (Preiser et al., 1990), and cardiac insufficiency (Bersin et al., 1997).   
 
DCA binds to PDK at an allosteric site that was mapped using the crystal structure of 
human PDK2 complexed to DCA (Knoechel et al., 2006).  This site is located in the N-
terminal domain and is formed by residues Leu53, Tyr80, Ser83, Ile111, Arg112, His115, 
Ser153, Arg154, Ile157, Arg158 and Ile161 (Knoechel et al., 2006 and Figure 9).  Most of these 
residues are conserved in all the known PDK isoforms (Figure 5).  The carboxylate group 
of DCA forms a salt-bridge with Arg158 while the chlorine is buried in the hydrophobic 
portion of the DCA binding site (Knoechel et al., 2006).  It is believed that binding of 
DCA to PDK prevents dissociation of ADP from the active site of PDK (Bao et al., 2004) 
thus locking PDK in its inactive form.   
 
DCA has proved not to be ideal for long term treatment of T2DM due to its toxicity 
(Stacpoole et al., 1979; Katz et al., 1981; Toth et al., 1992 and Yount et al., 1982).  The 
toxicity of DCA results from it being metabolized to glyoxylate which is converted to 
oxalate.  High amounts of oxalate lead to abnormal oxalate metabolism (Stacpoole et al., 
1990).  Furthermore, DCA stimulates thiamine-dependent enzymes which cause 
depletion of thiamine in the body (Stacpoole et al., 1990).  It is, therefore, imperative to 
investigate other useful drugs that can inhibit PDK activity for the therapy of diabetes and 
other metabolic disorders. 
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Figure 9: Interactions between DCA and the residues in the DCA binding site of 
PDK2. 
The DCA allosteric pocket in PDK is coloured according to CPK colour scheme where red indicates region 
with negative charge, blue a positive charge region and white a neutral region.  The DCA molecule is 
coloured cyan.  The red and yellow rings in DCA molecule denote the oxygen and chlorine atoms, 
respectively.  The green dotted line shows hydrogen bonds between DCA and Tyr80 while the solid grey 
line represents a salt bridge that is formed between Arg145 and DCA.  This image was generated using 
Swiss PDB Viewer (Guex and Peitsch, 1997) based on coordinates of 2BU8 (PDB code) (Knoechel et al., 
2006). 
Lue 53
Tyr 80
Arg 112
Ile111
Arg154
His115
Arg188
Ile157
3.1
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Ile161
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1.10.2  Remarks on protein kinases as drug targets  
 
Protein kinases have revealed themselves to be ideal targets for rationally designed 
inhibitory drugs.  Through this process, a number of inhibitors have been synthesized and 
had successful outcomes in clinical trials.  These inhibitors target different regions in the 
kinases, such as the nucleotide binding domain, the site of allosteric activation of the 
kinases, and the site of interaction between the kinase and other regulatory proteins. 
Examples of kinase inhibitors that bind the nucleotide domain include Iressa®, (Baker et 
al., 2001) and staurosporine (Prade et al., 1997).  Iressa® binds irreversibly to the EGFR 
tyrosine kinase by covalently binding the cysteine in the ATP binding pocket, and 
staurosporine binds to the adenosine pocket of the catalytic subunit of cAMP-dependent 
protein kinase.  These compounds are able to inhibit effectively the nucleotide binding 
site because it has a loop region that contains a conserved glycine-rich sequence.  The 
glycine residues in this site make the loop region very flexible in the absence of ATP thus 
allowing binding of small molecule inhibitors (Mohammadi et al., 1997; Huse and 
Kuriyan, 2002).  These inhibitors induce structural changes thus preventing substrate 
binding (Mohammadi et al., 1997).   
 
However, as the nucleotide binding domains are ubiquitous, specificity is a concern.  In 
attempts to address the specificity of kinase inhibitors, inactive forms of kinases are being 
targeted since they differ in structure (Noble et al., 2004).  This approach has been 
successfully employed in designing Gleevec, a specific inactive c-Abl kinase inhibitor 
(Nagar et al., 2003).  Gleevec acts by binding to the inactive form of c-Abl kinase thus 
locking the enzyme in its inactive conformation (Nagar et al., 2003).  An example of an 
inhibitor that binds to the allosteric site of kinases is BIRB 796.  It binds to human p38 
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MAP kinase and stabilises the conformation of the kinase that is incompatible with ATP 
binding thus preventing ATP attachment to the active site (Pargellis et al., 2002). 
 
1.11 Objectives  
 
PDK plays a significant role in glucose homeostasis through regulation of the PDC 
complex, and impaired functioning of PDC results in development metabolic disorders 
associated with abnormal glucose handling such as T2DM.  Amongst the isomers of 
PDK, PDK4 is believed to be the primary isoform that is implicated in insulin resistance 
and T2DM.  For that reason, it is important to find inhibitors of PDK4 for use in insulin-
resistance or T2DM therapy.   
 
To design inhibitors for PDK4, it is essential to understand its physical and chemical 
properties as well as its three dimensional structure.  ADP was chosen as a lead candidate 
for this study, since it is known to bind to the PDK active site as a by-product of ATPase 
activity.  Furthermore, ADP has been shown to inhibit PDK activity on its own as well as 
synergistically with pyruvate (Pratt and Roche, 1979).  The PDK binding site of ADP has 
previously been mapped in rat PDK2 (Steussy et al., 2001).   
 
In order to study the physical properties of PDK4, the hypothetical structure of PDK4 
was modelled on the resolved crystal structure of rat PDK2.  The primary focus of the 
study was the ADP binding site since it enabled the investigation of the interactions 
between ADP and rat PDK4.  Amino acid residues that were identified computationally 
to make contact with ADP were compared to those of rat PDK2 that are known to make 
contact with ADP.  Further, the rPDK4 protein was expressed in Escherichia coli and 
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purified using affinity and gel filtration chromatography.  The structure of PDK4 was 
then characterised using fluorescence spectroscopy and circular dichroism.  The purified 
rPDK4 protein was further confirmed to be rPDK4 protein using Western blot analysis 
and a kinase activity assay.  The binding of ADP and ATP to rPDK4 was studied using 
fluorescence quenching as both these ligands have been shown to quench the intrinsic 
tryptophan fluorescence of rPDK2 (Hiromasa et al., 2006).  
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2 Materials and Methods  
 
2.1 Materials  
 
A plasmid containing the rPDK4 gene was a gift from Dr Kirill M. Popov of the 
University of Missouri-Kansas City (USA).  Chromatographic resin used in this study 
(Sephacryl S-300HR and nickel-Sepharose), were purchased from Amersham 
Biosciences and Novagen®, respectively.  The PDK4 primary antibody used in the 
Western blot analysis of rPDK4 was purchased from Roche Diagnostics. The rPDK4 
substrate (Ac-YHGHSMSDPGVSYR) used in the PDK activity assay was synthesised by  
BIOPEP Peptide Synthesis at the Department of Biochemistry, University of 
Stellenbosch, South Africa.  The radio-labeled ATP ([γ-32 P] ATP) used to determine 
rPDK4 activity was purchased from Amersham Pharmacia Biotech.  All other reagents 
and chemicals used were of analytical grade.   
 
2.2 Modelling of rPDK4 
 
The protein sequences of rat PDK2 and PDK4 were aligned using ClustalW, version 1.83 
(Thompson et al., 1994).  Modelling of the structure of rPDK4 was exploited using the 
high sequence similarity between rPDK4 and rPDK2.  The structure of rPDK4 was 
modelled based on the coordinates obtained from the tertiary structure of rat PDK2 
(1JM6) by Steussy et al. (2001).  The quality of the modelled structure was verified using 
the WHAT IF program (Vriend, 1990) and Ramachandran plot. 
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2.3 Identification of amino acid residues that are crucial for interacting 
with ADP 
 
Since the rat PDK2 structure was co-crystallised with ADP, it was possible to study the 
putative ADP interaction with rPDK4.  In order to investigate further the ADP interaction 
with rPDK4, the ADP from rPDK2 was merged to rPDK4 using DeepView/Swiss PDB 
(http://au.expasy.org/spdbv/) (Guex and Peitsch, 1997).  The amino acids that play a role 
in hydrogen bonding interactions within a distance of 4 Å from ADP were investigated. 
 
2.4 Confirmation of rPDK4 in pET28A plasmid  
 
The rat cDNA was ligated into a pET28A vector and the resultant plasmid was 
transformed into Escherichia coli BL21 (DE3) cells that co-expressed the chaperones 
GroES/L.  These proteins were expressed in a second plasmid (pGROELS, Takara, 
Japan).  In order to confirm the presence of the rPDK4 gene, plasmid DNA was isolated a 
purified using the plasmid isolation kit from Promega as per the manufacturer’s 
instructions.  The isolated plasmid DNA was used as the template DNA in a polymerase 
chain reaction (PCR) using gene specific forward and reverse primers.  The nucleotide 
sequences for the forward and reverse primers were the following: (5'-
CCCTCCATGGTTGCACCATGAAGGC-3’) and (5'-ACCCTCGAGAGCTGGGTCTA 
CATGGCC-3').  Each PCR reaction mixture contained 0.2 µM of each primer, 200 µM 
of deoxyribonucleic triphosphates, 10 ng of template DNA, buffer and 1 Unit of Taq 
polymerase.  A forty cycle PCR reaction was performed with the following parameters: 
45 seconds at 94ºC for denaturation, 1 minute at 60ºC for annealing and 1 minute at 72ºC 
for extension.  The PCR product was cleaned using the PCR clean up kit from Promega 
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as per manufacture’s instructions.  The PCR product was then sent to Inqaba Biotech 
(South Africa) for sequencing.   
 
2.5 Expression of rPDK4 protein 
 
A glycerol stock of Escherichia coli BL21 [pET-PDK4 / pGROEL/S] (10 µl) was 
inoculated into Luria Broth medium (10 g/l yeast extract, 10 g/l tryptone and 5 g/l NaCl) 
containing 45 µg/ml kanamycin and 35 µg/ml chloramphenicol.  The cells were allowed 
to grow at 37°C.  After the A600 reached 0.7-0.8, the culture was transferred to room 
temperature and induced with 0.4 mM isopropyl-β-D-thiogalactopyranoside (IPTG).  
Incubation continued for another 20-24 h at room temperature.  After 20-24 h of 
induction, cells were harvested by centrifugation at 50 000 x g for 20 min, and 
subsequently the pellet was stored at -20°C until they were used.   
 
In order to test for expression of PDK, the harvested cells were resuspended in 10 ml of 
binding buffer (40 mM imidazole, 4 M NaCl, 160 mM Tris-HCl pH, 7.9) which was 
supplemented with 0.5 % (w/v) Triton X-100.  The resuspended cells were sonicated and 
centrifuged at 50 000 x g for 30 min at 4 °C.  The cleared cell lysate was analysed using 
sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) for rPDK4 
expression (see section 2.7).   
 
2.6 Purification of rPDK4 protein  
 
The rPDK4 protein was purified using affinity and gel filtration chromatography. 
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2.6.1 Affinity chromatography 
 
The cleared cell lysate was loaded onto a nickel-Sepharose column (7.5 ml bed volume) 
pre-equilibrated with the previously described binding buffer (see section 2.5). Once all 
the supernatant entered the resin, the column was washed with 5 volumes of binding 
buffer.  The unbound protein was eluted with washing buffer (480 mM imidazole, 4 M 
NaCl, 160 mM Tris-HCl, pH 7.9) and the fractions were being monitored at 280 nm.  The 
bound proteins were eluted with elution buffer (4 M imidazole, 2 M NaCl, 80 mM Tris-
HCl, pH 7.9).  The elution profile of the eluant was recorded by collecting 2 ml fractions 
and measuring the absorbance at 280 nm.  Eluted fractions were analysed using SDS-
PAGE (Section 2.7).  The fractions that contained PDK were pooled and desalted on a 
PD-10 column (Pharmacia) equilibrated with  storage buffer (20 mM Tris-HCl, 0.1 M 
NaCl, 0.5 mM EDTA, 0.05 % Triton X-100, 5 mM dithiothreitol (DTT), pH 8.0). 
 
2.6.2  Gel filtration chromatography  
 
Sephacryl S-300HR gel filtration media (Amersham Biosciences) with a fractionation 
range in relative molecular mass (Mr) of 1 x 104 - 1.5 × 106 was used for gel filtration 
chromatography.  After packing the Sephacryl S300HR resin into the column, it was 
equilibrated with storage buffer (as described in Section 2.6.1).  Gel filtration standards 
(Bio-Rad) with Mr  of 670 000 (bovine thyroglobulin), 158 000 (bovine gamma globulin), 
44 000 (chicken ovalbumin), 17 000 (horse myoglobin) and 1 350 (vitamin B-12) were 
used to create a size-exclusion standard curve.  The gel filtration selectivity curve was 
created for the column according to the protocol laid out in the Gel Filtration Principles 
and Methods Handbook by Amersham Biosciences (Uppsala, Sweden).  Blue dextrin (Mr 
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2x105) was used to determine the void volume (Vo) of the column.  The partially purified 
PDK sample from the affinity purification column was loaded onto the column using a 
flow rate of 0.5 ml/min and the elution was monitored at A280.  The eluted fractions that 
contained protein
 
were analysed using SDS-PAGE.   
 
The fractions that contained pure PDK protein were pooled and concentrated using 
Amicon ultra filtration unit.  The final preparation was made to 50 % (v/v) with glycerol 
and stored in 50 µl aliquots at -80°C.  
 
2.7 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-
PAGE)  
 
The purity and homogeneity of the rPDK4 protein were assessed using 10 % SDS-PAGE 
as described by Laemmli (1970).  Prior to loading of protein samples onto the gel, the 
proteins were incubated with SDS-PAGE sample buffer (0.125 M Tris-HCl, 4 % (w/v) 
SDS, 20 % (v/v) glycerol, 5 % (v/v) β-mercaptoethanol and 0.02 % (w/v) bromophenol 
blue, pH 6.8) for 5 minutes at 95oC.  Gels were electrophorised for one hour at 200 V.  
Staining was performed using Coomassie Stain (40 % methanol; 0.7 % acetic acid; 
0.075 % Coomassie dye).  Gels were destained with Coomassie destain (40 % methanol; 
0.7 % acetic acid).  Molecular weight markers (Fermentas) were used as standards with 
relative molecular masses of 250 000, 150 000, 100 000, 75 000, 50 000, 37 000, 25 000, 
15 000 and 10 000.   
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2.8 Protein concentration determination  
 
2.8.1 Beer-Lambert law 
 
The protein concentrations were determined spectrophotometrically by applying the 
Beer-Lambert law. 
 
The Beer-Lamberts law:  A = ελcl     (1) 
 
where ελ is the molar extinction coefficient at wavelength λ, c is the concentration and l is 
the pathlength of the light through the solution in the cuvette.  The extinction coefficient 
of the dimeric form of PDK was calculated using equation 2.  The primary amino acid 
sequence of rPDK4 (Figure 5) was used to obtain the number of tryptophan, tyrosine and 
cysteine residues. 
 
ε(280)(M-1 cm-1 ) = (#Trp)(5550) + (#Tyr)(1340) +(#Cys)(150)  (2)  
       =2200 + 21440 + 1500  
       =25140  
 
2.9 Western blot analysis 
 
The transfer of proteins from SDS-PAGE to polyvinylidene difluoride membranes (0.45 
µm pore size, Immobilon-P, Millipore Corp., Bedford, MA) was accomplished with a 
semi dry Trans-Blot transfer system (Bio-Rad Laboratories, Inc.) with a transfer buffer 
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consisting of 25 mM Tris-HCl, 192 mM glycine, and 20 % methanol for one hour at 
150 mA.  Membranes were blocked for 90 min at room temperature in Tris buffered 
saline (TBS) containing Tween 20 (20 mM Tris (pH 7.6), 137 mM sodium chloride, 0.1 
% Tween-20 (TBST)) and 2 % dried non-fat milk powder.  Membranes were incubated 
overnight in TBST at 4 ºC with anti-PDK4 primary antibody at a dilution of 1:5000.  
After incubation with primary antibody, blots were incubated with antirabbit IgG 
horseradish peroxidase-conjugated antibodies at a dilution of 1:2500 in TBST for 90 min 
at room temperature.  After three washes in TBST, immunoreactive bands were detected 
using the enhanced chemiluminescence detection system (Amersham Pharmacia Biotech, 
Arlington, IL), according to the manufacturer’s instructions.   
 
2.10  Size-exclusion high pressure liquid chromatography 
 
Size-exclusion chromatography was performed on the partially purified PDK sample.  
The column used was TSK –Gel ® G2000SWXL.  The column was equilibrated with 50 
mM Na2PO4 pH 6.8.  The buffer was filtered and degassed before use.  An LKB 2150 
pump (Pharmacia) was used to maintain the flow rate at 0.5 ml/min.  Gel filtration 
standards (Bio-Rad) with relative molecular masses of 670 000 (bovine thyroglobulin), 
158 000 (bovine gamma globulin), 44 000 (chicken ovalbumin), 17 000 (horse 
myoglobin) and 1 350 (vitamin B-12) were used to create a size-exclusion standard 
curve.  The partially purified sample was then loaded and injected onto the column via 
the load/inject port, with the elution profile recorded at 280 nm using a Spectra series UV 
100 detector.  The protein was eluted with 50 mM Na2PO4 (pH 6.8) from the column at 
0.5ml/min and the eluant was monitored at 280 nm.   
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2.11 PDK activity assay 
 
The rPDK4 activity was determined using a modified published method (Jackson et al., 
1998).  Briefly, the activity of rPDK4 was tested in a 30 µl reaction which contained 
5µM of rPDK4, 25 µM of E1α peptide of PDC as a substrate (Ac-
YHGHSMSDPGVSYR), [γ-32 P] ATP and activity assay buffer.  The activity assay 
buffer contained the following: 44 mM Mops, 22 mM KH2PO4, 0.56 mM EDTA, 2 mM 
MgCl2, 33 mM KCl and 2.2 mM DTT (pH 7.5) .  The reaction was started with the 
addition of 2.5 µl of 250 µCi of [γ-32P] ATP.  This was followed by incubating the assay 
reaction at 37oC for one hour.  The reaction was terminated by addition of 10 µl of SDS-
PAGE sample buffer and further incubating the sample at 90 oC for five minutes.  The 
sample was loaded on 10 % SDS-PAGE gel and electrophorised as described in section 
2.7.  This was followed by staining the 10 % SDS-PAGE with Coomassie Stain and 
destaining overnight with Coomassie destain containing 10 % of glycerol.  The gel was 
subsequently dried under vacuum and exposed on X-ray film at -70 oC overnight.  
 
The activity of PDK is inhibited by ADP and pyruvate (Pratt and Roche, 1979).  ADP 
and pyruvate were therefore also added to the kinase assay reaction in order to investigate 
their ability to inhibit the activity of rPDK4.  The final concentration of ADP and 
pyruvate in the PDK activity assay were 50 mM each.  The inhibition of rPDK4 activity 
would be shown by the inability of rPDK4 to phosphorylate the E1α peptide of PDC.  
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2.12 Circular dichroism 
 
The far–UV CD spectrum of rPDK4 protein was measured 20oC at using a Jasco J-810 
spectropolarimeter.  The sample chamber was constantly flushed with nitrogen.  Far-UV 
CD spectra were recorded from 200 to 250 nm in a 0.2 cm quartz curvette at 1 nm 
intervals using a protein concentration of 2 µM in 20 mM sodium phosphate buffer, pH 
7.5.  The spectra were averaged over ten accumulations.  The spectrum of the buffer 
control was subtracted from the experimental spectra. 
 
2.13 Fluorescence spectroscopy  
 
A fluorescence spectrum of PDK4 protein was obtained at 20 oC using a Perkin-Elmer LS 
50 B spectrometer.  The PDK4 protein was excited at either 280 nm or 295 nm.  The 
excitation and emission bandwidths were set at 5 nm and the emission spectra collected at 
200 nm/min with ten accumulations.  The protein concentration used was 5 µM in 50mM 
potassium phosphate buffer, pH 7.5 containing 0.5 mM EDTA, 2.0 mM MgCl2.  The 
fluorescence values were corrected for the buffer as blank.   
 
2.14 Effects of ADP and ATP binding on rPDK4 intrinsic fluorescence 
 
The binding of ADP and ATP to rPDK4 was studied by measuring the quenching of 
tryptophan fluorescence (Hiromasa et al., 2006).  The rPDK4 protein at (5 µM in 50 mM 
potassium phosphate, 0.5 mM EDTA, 2.0 mM MgCl2, pH 7.5), was titrated with either 
ADP or ATP in a concentration range of 0 to 250 µM, and the fluorescence was 
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measured.  The protein was excited at 295 nm and the fluorescence emission was 
recorded at 350 nm.   
 
In the data analysis, the fluorescence of rPDK4 in the absence of ligand is the maximum 
fluorescence (Fmax) at 350 nm (Figure 26).  The addition of ligand (ADP or ATP) to 
rPDK4 quenches the fluorescence (F) of rPDK4 relative to the absence of ligand.  The 
percentage of quenching by ligands was therefore, calculated according to equation 3. 
 
Percentage quenching = 100* (Fmax - F)    (3) 
     Fmax  
 
where, Fmax is the maximum fluorescence of rPDK4 in the absence of the ligand and F is 
the fluorescence of rPDK4 in the presence of ADP or ATP. 
 
Sigma plot V8.0 (Jandel Corporation) was used to determine the dissociation constant 
(Kd) of ADP or ATP, the data was fitted on hyperbolic (Figure 28B and Figure 29B) 
curve using equation 4. 
 
F =  Fmax [S]        (4) 
            Km+ [S] 
 
where, Km is the Michaelis constant in mM (Km=Kd) giving the Kd value and S is the 
concentration of the ligand (ATP or ADP).  
 
The data was further plotted on a Hill plot using (Log (F/Fmax - F) against log [S]) to 
determine the Hill constant (nH).   
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3 Results  
 
3.1 Homology modelling of rPDK4 
 
To find an appropriate template to model the structure of rPDK4, a BLAST 
(http://www.expasy.org/tools/blast; Altschul et al., 1997) search using the primary 
sequence of rPDK4 was performed against the structural Protein Database (PDB).  The 
results from the search are shown in Table 1 with 1JM6 (rat PDK2 PDB code) giving the 
best E value.  The closer the E value is to zero, the better the chance of a correlation 
between the peptide sequences of any two proteins compared.  This, therefore, means 
they are likely to be structurally and functionally related.  
 
Table 1: Results of a BLAST search for sequence homologues to rPDK4 that have a 
known tertiary structure 
 
PDB 
number 
Description  Resolution Ǻ E- value 
1jm6 Pyruvate dehydrogenase kinase Isozyme 2 
containing ADP 
2.50 e-135 
1gkz Branched–chained α–ketoacid dehydrogenase 
complexed with ADP 
2.2 2e-38 
1gjv Branched–chained α–ketoacid dehydrogenase 
complexed with ATP-gamma 
2.7 2e-37 
1gkx Branched–chained α–ketoacid dehydrogenase 
complexed with ADP 
2.3 2e-47 
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The primary amino acid sequences of rPDK2 and rPDK4 were also aligned using the 
alignment program ClustalW (http://www.ebi.ac.uk/Tools/clustalw/).  The alignment 
results showed 65 % sequence similarity between the two proteins (Figure 10).  
Successful modelling requires at least one experimentally solved three-dimensional 
structure that should have more than 40 % amino acid sequence identity to the target 
sequence (Brenner, 2001 and Schwede et al., 2003).  Therefore, the BLAST search and 
sequence alignment result shows that the rPDK2 structure, 1JM6, is a suitable template 
for modelling rPDK4.   
 
The modelled structure of rPDK4 was built using rPDK2 as a template using SWISS-
MODEL (Guex and Peitsch, 1997).  The proposed homology model of rPDK4 is shown 
in Figure 11.  The quality of the modelled structure of rPDK4 was verified using the 
WHATIF program (Vriend, 1990) and the Ramachandran plot (Ramachandran and 
Sasiskharan, 1968).  The Z scores of rPDK4 structure obtained from the WHATIF 
program was within the accepted range.  The Ramachandran plot indicated that the 
modelled rPDK4 structure has good geometry (Figure 12).  Most of the non-glycine 
residues were found in the favoured and allowed regions, with the exception of Ala33, Pro 
134
 and Ala313.  Although, some glycine residues were also found in the disallowed 
regions, this is acceptable since glycine has a hydrogen atom as a side chain which 
enables it to adopt a number of different conformations.   
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rPDK2           MRWFRALLKNASLAG----APKYIEHFSKFSPSPLSMKQFLDFGSSNACEKTSFTFLRQE 56 
rPDK4           MKAARFVMRSASSLGNAGLVPREVELFSRYSPSPLSMKQLLDFGSENACERTSFSFLRQE 60 
                *:  * :::.**  *    .*: :* **::*********:*****.****:***:***** 
 
 
 
 
 
rPDK2           LPVRLANIMKEINLLPDRVLSTPSVQLVQSWYVQSLLDIMEFLDKDPEDHRTLSQFTDAL 116 
rPDK4           LPVRLANILKEIDILPEHLVNTPSVQLVKSWYIQSLMDLVEFHEKSPEDQKVLSDFVDTL 120 
                ********:***::**::::.*******:***:***:*::** :*.***::.**:*.*:* 
 
 
 
 
rPDK2           VTIRNRHNDVVPTMAQGVLEYKDTYGDDPVSNQNIQYFLDRFYLSRISIRMLINQHTLIF 176 
rPDK4           VKVRNRHHNVVPTMAQGILEYKDNCTVDPVTNQNLQYFLDRFYMNRISTRMLMNQHILIF 180 
                *.:****::********:*****.   ***:***:********:.*** ***:*** *** 
 
 
 
rPDK2           DGSTNPAHPKHIGSIDPNCSVSDVVKDAYDMAKLLCDKYYMASPDLEIQEVNATNATQPI 236 
rPDK4           SDSK-TGNPSHIGSIDPNCDVVAVVEDAFECAKMLCDQYYLTSPELKLTQVNGKFPGQPI 239 
                ..*. ..:*.*********.*  **:**:: **:***:**::**:*:: :**.. . *** 
 
 
 
 
rPDK2           HMVYVPSHLYHMLFELFKNAMRATVESHESSLTLPPIKIMVALGEEDLSIKMSDRGGGVP 296 
rPDK4           HIVYVPSHLHHMLFELFKNAMRATVEHQENRPFLTPVEATVVLGKEDLTIKISDRGGGVP 299 
                *:*******:**************** :*.   *.*::  *.**:***:**:******** 
 
 
                          α11 α12                                                α13               β6        β7 
rPDK2           LRKIERLFSYMYSTAPTPQPGTG-GTPLAGFGYGLPISRLYAKYFQGDLQLFSMEGFGTD 355 
rPDK4           LRITDRLFSYTYSTAPTPVMDNSRNAPLAGFGYGLPISRLYAKYFQGDLNLYSMSGYGTD 359 
                **  :***** *******  ... .:***********************:*:**.*:*** 
 
 
 
 
rPDK2           AVIYLKALSTDSVERLPVYNKSAWRHYQTIQEAGDWCVPSTEPKNTSTYRVS- 407 
rPDK4           AIIYLKALSSESIEKLPVFNKSAFKHYQMSSEADDWCIPSKEPKNLSKEKLAV 412 
                *:*******::*:*:***:****::***  .**.***:**.**** *. :::  
 
Figure 10: Alignment of rPDK2 and rPDK4.  
The sequence was aligned using ClustalW, version 1.83 (Thompson et al., 1994).  The sequences of the 
PDK isomers were obtained from Genbank and their accession numbers are as follows: rPDK2-Q64536 
and rPDK4-O54937.  The red and yellow colours indicate α helices and β strands, respectively.  The amino 
acids that are shown in bigger font, and in bold, are involved in the binding of ADP by PDK protein.  The 
tryptophan residues (W) are shown in green.  The secondary structure information was taken from 
http://www.biochem.ucl.ac.uk/bsm/pdbsum/1jm6.  The similarity between the two sequences was 
determined using the NCBI BLASTP 2.2.8 (Altschul et al., 1997).   
α6             α7                   β1                         α8       
                                      α9                                β2 
     β3              α10                                 β4               β5 
         α1                        α2                      α3 
 β7 
   α3                α4               α5                                α6       
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Figure 11: Ribbon representation of the homology modelled three dimension 
structure of rat PDK4.  
Ribbon presentation of human PDK4 dimer modelled using SWISS-MODEL based on coordinates 
published by Steussy et al. (2001) (1JM6) viewed down the 2-fold axis.  α-Helices are coloured in red, β-
strands are coloured in yellow, and the loop regions are coloured in pink.   
 
 
 
Figure 12: Ramachandran plot of rat PDK4 structure.   
Yellow lines indicate favoured conformations of amino acid residues, and blue lines indicate additional 
allowed conformations.  Points that are boxes indicate glycine residues and crosses indicate other residues. 
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The overall structural topology of rPDK2 seems to be preserved in rPDK4 according to 
the SWISS-MODEL homology modelling.  The structural alignments between these two 
structures give a root mean square deviation (RMSD) value of 1.7 Å using the backbone 
of all atoms of both structures (Figure 13).  The RMSD value is used to measure the 
structural similarity between proteins structures (Maiti et al., 2004).  This RMSD value of 
1.7 Å obtained from aligning the rPDK4 model and its template, implies that the overall 
structural topology is highly conserved and does not deviate far from the crystal structure 
of PDK2.  In the structural alignment, the modelled rPDK4 is coloured using the 
confidence factor which indicates regions that have deviated from the template.  The 
regions that have deviated significantly are in coloured red.  The modelled structure of 
rPDK4 is relatively good since most of the structure is coloured green (Figure 13) 
indicating no deviation from the template structure.  However, there are regions of 
rPDK4 that are coloured red.  These regions are (a) amino acid residues Phe28- Glu31 
which form a loop connecting helices α2 and α3, (b) amino acid residues Glu125- Pro134 
which form a loop region connecting helix α7 and β1 strand, (c) residues Phe165- Pro173 
which are part of a loop region connecting helices α8 and α9 and (d) residues Asp305- 
Lue312 which are part of the loop region connecting helices α12 and α13.  The above 
regions are coloured red because they were constructed ab initio since they are missing in 
the crystal structure of rPDK2 and this lowers the level of confidence in the integrity of 
constructed region of the rPDK4 modelled structure.   
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Figure 13: Structural alignment of rat PDK2 and rat PDK4 monomers.   
Rat PDK4 is coloured by confidence factor (green and red) where the coloured red shows the regions that 
were constructed ab initio.  The rat PDK2 is coloured blue.  
 
3.2  The rPDK4 nucleotide binding site  
 
The ADP binding site in rPDK4 was located by identifying the presence of binding 
pockets on the protein surface.  Figure 14 shows two cavities indicated in red and blue 
colouring on the rPDK4 protein surface which is coloured yellow.  The red coloured 
cavity was determined to be 261 Å and this site has not yet been characterised.  The blue 
coloured cavity has a surface area of 94 Å which correspond to the size of ADP binding 
pocket in rPDK2.  The manual docking of ADP to rPDK4 also confirmed the 94 Å cavity 
as the ADP binding pocket.  The ADP binding pocket consists of β-strand-loop-α-helix 
structure with the loop region being glycine rich.  This structure is a characteristic feature 
of the phosphate binding site (Schulz et al., 1986).  
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Figure 14: Molecular surface of rPDK4 showing the ADP binding site. 
The image was generated using Swiss PDB Viewer (Guex and Peitsch, 1997).  The molecular surface of 
rPDK4 is coloured yellow.  The blue shaded region in the rPDK4 surface is the ADP binding site which 
contains an ADP molecule coloured according to CPK colour scheme .  The red coloured region is a 
potential ligand binding site that has not yet been characterised.   
 
 
The amino acids in the ADP binding site that play a role in the interaction between ADP 
and rPDK4 through hydrogen bond formation, were identified using DeepView/Swiss 
PDB Viewer (Guex and Peitsch, 1997).  Hydrogen bonds that were formed within a 
distance of 4 Å from ADP are shown by dotted green lines in Figure 15.  The ADP 
binding site of rPDK4 is homologous to that of rPDK2.  Further, the amino acids that are 
involved in the binding of the ADP molecule in rPDK4 are the same as those in rPDK2 
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(Figure 15).  The positions of the residues that are involved in the binding of ADP are 
shown in Figure 10.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: The interaction between rPDK4 and ADP and rPDK2 and ADP.  
The image was generated using Swiss PDB Viewer (Guex and Peitsch, 1997).  A: rat PDK2 interacting 
with ADP. B: rat PDK4 interacting with ADP.  PDK is coloured in CPK colour scheme and ADP is 
coloured in pink. Hydrogen bonds between PDK and ADP are shown in dotted green lines.  The 
participating residues are labelled using yellow font.  
 
 
The ionic and hydrophobic interactions between ADP and rat PDK2 active site were 
investigated using Swiss PDB Viewer.  The results are shown in Figure 16.  In the rPDK4 
ADP binding site, Arg246 and Asp278 were the two only residues that formed ionic 
Asp 282 
Asn 247 
Leu 322 
Phe 318 Gly 319 
Thr 302 
Ser 301 
Arg 250 
Asp 278 
Thr 298 
Leu 319 
Gly 316 
Phe 315 
Ser 297 
Arg 246 
Asn 243 
  A   B 
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interactions with ADP.  The rest of the amino acids were either involved in hydrophobic 
or hydrogen bonds.  
 
 
 
 
 
Figure 16: Non-covalent interactions between ADP and the residues in the 
nucleotide binding domain of rPDK4. 
The ADP molecule is coloured according to CPK where red indicates region with negative charge.  The 
dotted green lines indicate hydrogen bonds between ADP and residues of rPDK4.  The residues of rPDK4 
are coloured according to their properties with red: acidic, blue: basic, yellow: polar and green: non polar.  
 
Leu 291 
Leu 319 
Leu 291 
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3.3 Purification and characterisation of rPDK4 
 
3.3.1 Confirmation of rPDK4 in pET28A plasmid  
 
The pET28/rPDK4 clone used in this study was a gift. It was, therefore, necessary to 
initially confirm whether it contained the rPDK4 gene.  Plasmid DNA was isolated from 
five separate colonies of Escherichia coli BL21 [pET28/rPDK4] and used for the 
amplification of the PDK4 gene.  As expected, a band of approximately 1.3 kb was 
obtained from all the colonies (Figure 17) and the 1.3 kb corresponds to the size of the 
PDK gene.  The 1.3 kb PCR product was sequenced.  The results from sequencing were 
submitted for a BLAST search (http://www.ncbi.nlm.nih.gov/BLAST) and gave a 100 % 
match to the nucleotide sequence of rPDK4.  
 
3.3.2 Expression of rPDK4  
 
PDK4 protein expression was induced as described in Section 2.5 using 0.4 mM of IPTG.  
Figure 18 shows the level of protein overproduction.  High levels of protein expression 
were obtained between 16 to 24 hrs of induction (Figure 18, Lane 2 to Lane 4).  The 
PDK4 protein was expressed and this was confirmed by the band at about 50 kDa.  The 
predicted molecular mass of PDK4 is ~ 50 kDa.  A band with low levels of induction was 
seen at 50 kDa, however a strongly induced band was seen at around 60 kDa.  This 
protein was assumed to be GroEL (the bacterial heat shock protein 60 / Hsp60) since the 
PDK4 clone was transformed into Escherichia coli BL21 (DE3) cells that co-expressed 
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the chaperone GroEL with its co-chaperone GroES.  They are the other proteins that were 
also induced during the expression of rPDK4 (Figure 18). 
 
 
 
 
 
Figure 17: Amplification of the PDK4 gene from pET28/rPDK4 using gene specific 
forward and reverse primes.   
Lane LM: contains the GeneRuler marker.  Lanes 1 to 6: show the 1.3 kb gene of pET28/rPDK4.  The 
molecular mass of the indicated bands are shown.   
 
The expression of rPDK4 seemed low and it was therefore crucial to establish whether 
the rPDK4 protein was insoluble and thus located in the pellet.  The cells that expressed 
high amounts of rPDK4 (induced for 24 hrs) were sonicated and centrifuged.  Both the 
cleared cell lysate and pellet were analysed by SDS-PAGE for the presence of rPDK4.  
Figure 18, lane 6 shows that there was no significant amount of rPDK4 located in the 
pellet.  Hence, rPDK4 was soluble.   
 LM   L1  L2  L3   L4    L5    L6    
 
1.5 kb  1.3 kb 
2.5 kb 
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Figure 18: Expression of rPDK4 protein.  
Lane M: Protein Ladder Marker; Lane1: contains un-induced (No IPTG) protein samples.  Lanes: 2 to 5 
show the induced protein samples.  Samples were taken at 4 hourly intervals.  Lane 2: 24 hrs; Lane 3: 20 
hrs; Lane 4: 16 hrs; Lane 5: 12 hrs.  Lane 6: contains insoluble proteins in the pellet after 24 hours of 
induction.   
 
3.3.3 Affinity chromatography 
 
After induction, the rPDK4 protein was purified using a nickel-Sepharose column under 
native conditions as outlined in the Material and Methods section 2.6.1.  The purity and 
homogeneity of the rPDK4 was assessed using SDS-PAGE (Figure 19).  Figure 19 lane 4 
and lane 5 show proteins that did not bind to the nickel column while lane 2 and lane 3 
show proteins that washed off during the washing steps.  The proteins that eluted in the 
wash step included the highly expressed 60 kDa protein.  During the wash steps there 
was, however a very small amount of PDK4 that was lost and this is confirmed by the 
band at about 50 kDa as seen in Figure 19 lanes 2 and 3.  The rPDK4 protein was eluted 
 
                          LM                   L1         L2         L3      L4       L5       L6 
60 kDa 
50 kDa 
10 kDa 
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from the nickel column by using high concentrations of imidazole and sodium chloride.  
Figure 19 lane 1 shows that using nickel affinity column could only partially isolate 
PDK4 since there are still other proteins present.   
 
3.3.4 Identification of rPDK4 by Western blotting  
 
At this point, it was necessary to confirm whether the 50 kDa protein obtained through 
affinity chromatography was indeed rPDK4.  It was decided to perform Western blot 
analysis on the partially purified protein from nickel affinity column using antibodies that 
are specific for rPDK4 protein.  The protein that was thought to be rPDK4 gave a signal 
when treated with antibodies specific to rPDK4 protein (Figure 20).  The signal was 
obtained at 50 kDa and this molecular weight corresponds to that of rPDK4.  
 
 
 
Figure 19: 10% SDS-PAGE gel showing purification of histidine tagged rPDK4 
protein using nickel affinity chromatography.  
Lane M: Protein Ladder Marker; Lane 1: contains the eluant from nickel affinity column; Lane 2: shows 
proteins that washed off with binding buffer; Lane 3: shows proteins that washed off with washing buffer.  
Lanes 4 and 5: contains proteins that did not bind to the column.   
LM            L1                 L2       L3      L4      L5 
50 kDa 
60 kDa 
 47 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: (A) 10% SDS-PAGE gel showing partially purified rPDK4 protein using 
nickel affinity chromatography, and (B) related Western blot analysis showing 
detection of rPDK4 protein.  
Lane M: Protein Ladder Marker; Lane 1 to Lane 3: contains partially purified PDK4 protein with 100 µg, 
150 µg and 200 µg of protein, respectively.  Figure 20B: Western Blot detection of rPDK4 based on the 
samples on the SDS-PAGE gel Figure 20A.  
 
3.3.5 Size-Exclusion chromatography 
 
Purification of rPDK4 using nickel affinity chromatography did not result in pure rPDK4 
protein.  SDS-PAGE analysis showed that the rPDK4 protein was contaminated with 
other proteins (Figure 20A).  It was, therefore, necessary to subject the partially purified 
enzyme to another purification step which was gel filtration.  At present there is a vast 
selection of gel filtration methods with different exclusion limits.  In order to select the 
60 kDa 
10 kDa 
50 kDa 
LM    L1     L2      L3 
 PDK4 
A B 
LM   L1    L2     L3    L1    L2     L3 
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media that is most likely to give a good separation, the partially purified rPDK4 protein 
was analysed using SE-HPLC under native conditions.   
 
A standard protein elution profile and corresponding standard curve were generated using 
molecular mass standards and a TSK –Gel ® G2000SW column.  Native SE-HLPC 
confirmed that the rPDK4 purified through nickel affinity column was indeed 
contaminated with other proteins (Figure 21A).  A protein with molecular mass of 96 
kDa (retention time of 113 minutes) was obtained (Figure 21A).  This molecular mass 
corresponds to the dimeric form of PDK (Steussy et al., 2001 and Popov et al., 1999).  
The molecular masses of other proteins contaminating the rPDK4 were found to be 279 
and 139 kDa and these proteins are unlikely to be heat shock proteins.  The standard 
curve of the elution profile for the protein standards is shown in Figure 21B.  The 
molecular mass standard curve was used to estimate the mass of the proteins contained in 
the partially purified rPDK4 sample.  Based on the SE-HPLC results, Sephacryl S-300HR 
gel filtration media (fractionation range of 1 x 104-1.5 × 106) was chosen to further purify 
rPDK4 from its contaminants.  
 
A standard protein elution profile and corresponding standard curve were generated using 
molecular mass standards and Sephacryl S-300HR column.  The proteins eluting from 
Sephacryl S-300HR column are shown in Figure 22 and a protein peak with the retention 
time of 116 minutes was observed.  The molecular mass of this peak was estimated to be 
97 kDa which corresponds to the dimeric form of PDK protein.  Fractions 28 to 38, 
giving a total volume of 10 ml, were pooled and concentrated to 500 µl using Vivaspin 
20 with a 30 kDa membrane cut-off.  This protein sample was further confirmed to be 
rPDK4 using SDS-PAGE gel and Western blot analysis (Figure 23).  
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Figure 21: SE-HPLC elution profile of partially purified rPDK4. 
The elution profile of partially purified rPDK4 protein using a TSK–Gel ® G2000SW column.  Briefly, the 
partially purified rPDK4 protein was injected into the SE-HPLC column and the effluent was monitored at 
280 nm.  The retention times are shown in brackets next to the protein peaks.  The relative molecular 
masses of the proteins that eluted from the SE-HPLC column were estimated using the standard curve in 
Figure 21B.   
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Figure 22: Protein elution profile from Sephacryl S-300HR of partially purified 
rPDK4.   
The partially purified rPDK4 from the affinity chromatography step was concentrated 10 fold using a 30 
kDa cut-off membrane.  A total volume of 2 ml of protein (6 mg) was loaded onto the Sephacryl S-300HR 
column and eluted using sodium phosphate buffer with a flow rate of 0.5 ml/min.  The elution of the 
protein was monitored at 280 nm.   
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Figure 23: Purification of rPDK4 protein by gel filtration.  
The 10 % SDS-PAGE gel analysis of rPDK4 from gel filtration is depicted in A.  Lane LM: shows the 
protein ladder marker, and L1 contains the eluant from gel filtration with retention time of 116 minutes.  
The Western blot analysis of protein sample on the SDS-PAGE gel is shown in B.   
 
3.3.6 Activity of rPDK4 
 
It was of importance to determine whether the isolated rPDK4 protein was catalytically 
active.  PDK proteins are known to phosphorylate three serine residues (Ser264, Ser271, 
Ser203) in the E1α subunit of PDC (Sale and Randle, 1981).  Jackson et al. (1998) 
demonstrated that rPDK2 protein can phosphorylate the peptide Ac–
YHGHSMSDPGVSR since it resembles the protein sequence region of E1α that is 
phosphorylated by PDK proteins.  The rPDK4 protein isolated in this study was found to 
be active since the data in Figure 24 demonstrates that the peptide was phosphorylated.  
PDK proteins are reported to undergo autophosphorylation (Popov et al., 1993; Thelen et 
al., 2000) and lane 2 in Figure 24 demonstrates this.  The presence of ADP or pyruvate, 
or both, in the peptide phosphorylation assay inhibited rPDK4 autophosphorylation as 
A B 
LM          L1   
50 kDa  
50 kDa  
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well as the phosphorylation of the peptide (Figure 24, Lanes 3 and 4).  This is consistent 
with published data which reports ADP and pyruvate are amongst the inhibitors of PDK 
enzymes. 
 
 
 
 
Figure 24: Autoradiograph showing the auto-phosphorylation of rPDK4 and 
peptide phosphorylation.  
The peptide was phosphorylated as described in section 2.11.  The proteins were separated by 10% SDS –
PAGE gel. The auto-phosphorylated rPDK4 and the phosphorylated peptide were detected by 
autoradiography.  L1: contains a negative control (no rPDK4 protein); L2: shows an auto-phosphorylated 
rPDK4 and phosphorylated peptide; L3 and L4: shows inhibition of rPDK4 auto-phosphorylation and 
phosphorylation of peptide by ADP and pyruvate respectively.   
 
3.3.7 Circular dichroism (CD) 
 
Far-UV CD was used to study the secondary structural content of the purified rPDK4 
protein.  The far–UV CD spectrum shows that rPDK4 displays two ellipticity minima at 
208 and 222 nm (Figure 25).  These wavelength minima are an indication of a protein 
with high helical content and which is consistent with the structure of PDK proteins that 
contain about 69 % α-helices (Steussy et al., 2001 and Figure 11).   
     L1         L2         L3        L4 
 rPDK4 
Peptide 
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Figure 25: Far-UV CD spectra of rPDK4. 
The rPDK4 protein (2 µM) in phosphate buffer was subjected to circular dichroism to determine its 
secondary structure content.  The spectrum of the buffer control was subtracted from the experimental 
spectra.   
 
3.3.8 Fluorescence spectroscopy   
 
Amino acid sequence analysis of rPDK4 shows that it contains tyrosine and tryptophan 
residues (Figure 10).  These amino acid residues fluoresce when excited at 280 nm.  
Fluorescence spectroscopy was therefore used to further characterize rPDK4.  The basal 
fluorescence of rPDK4 was measured by exciting the rPDK4 at 280 nm where both the 
tyrosine and tryptophan are known to fluoresce.  The rPDK4 protein was also excited at 
295 nm exclusively for tryptophan residues.  The excitation of PDK4 protein at 295 nm 
with emission wavelength between 300 and 420 nm showed a broad peak with a peak 
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centre of 350 nm whereas exciting the rPDK4 at 280 nm gave higher fluorescence 
intensity with peak centre of 318 nm (Figure 26).   
 
 
Figure 26: Basal fluorescence spectrum of 5 µM rPDK4 protein.  
Briefly, 5 µM of rPDK4 protein was excited at 280 nm (black solid circles) and 295 nm (clear circles) and 
the emission wavelength was measured between 300 and 420 nm. 
 
3.3.9  Effects of ADP and ATP binding on the rPDK4 intrinsic fluorescence  
 
Hiromasa et al. (2006) reported that mutation of Trp383 on human PDK2 to phenylalanine 
results in the loss of basal fluorescence of human PDK2 when excited at 295 nm.  This 
meant that Trp383 was the main tryptophan residue responsible for the fluorescence when 
human PDK2 is excited at 295 nm and the other two tryptophan residues on human 
PDK2 (Trp79 and Trp371) were buried within the structure thus becoming solvent 
inaccessible (Hiromasa et al., 2006; Figure 27).   
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In the tertiary structure of human PDK2, Trp383 is situated close to the binding site 
(Figure 27).  The fluorescence emitted by Trp383 can therefore be used to monitor any 
effects of ligand binding (ADP or ATP) to the binding site.  It would therefore be 
expected to see a change in the fluorescence emission when a ligand (ADP or ATP) binds 
in the PDK active site, since the presence of a ligand would affect the environment of 
Trp383.  In an event where there is no binding the fluorescence intensity is unlikely to 
change.   
 
 
 
Figure 27: The structure of human PDK2 monomer (2bu2) complex with ATP 
showing the location of the tryptophan residues.  
The tryptophan residues are shown in blue and the ADP molecule is coloured red. The region circled in 
white depicts the nucleotide binding site.   
 
Primary sequence analysis of rPDK4 showed that it contained two tryptophan residues, 
Trp81 and Trp395.  The Trp395of rPDK4 corresponds to Trp383 in human PDK2.  It was 
Trp383 
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therefore hypothesised that Trp395 in rPDK4 could also be used to study binding of ADP 
and ATP.  In the modelled structure, the Trp395 residue is in a loop region at the tail of the 
C-terminal domain, but, when the PDK4 is correctly folded it is located in close 
proximity to the active site (Figure 27).  It was therefore hypothesized that Trp395 in 
rPDK4 will also be situated close to the active site in the tertiary structure of rPDK4 and 
hence might be sensitive to the binding of ADP and ATP.    
 
It is shown in Figure 28A, that an increase in the concentration of ADP present in 
solution with rPDK4 results in a decrease in tryptophan fluorescence intensity putatively 
given by Trp383.  The dissociation constant (Kd) of ADP was determined to be 37 µM 
when the data was fitted on the hyperbolic fit using equation 4 (Figure 28B).  Steussy et 
al (2001) reported that each monomer of PDK contains an ADP binding site.  It was, 
therefore, necessary to establish further whether there was any cooperativity between the 
two ADP binding sites of rPDK4.  The data was further analysed using a Hill plot (Figure 
28C).  The Hill plot gave a Hill coefficient (nH) value of 0.7 which is indicative of 
negative cooperativity within the two ADP binding site of rPDK4.  The nH of 0.7 differs 
with the value of 1 published by Hiromasa et al. (2006) which described positive 
cooperativity within the two human PDK2 binding sites of ADP.   
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Figure 28: Quenching of basal rPDK4 fluorescence at 350 nm by ADP. 
The rPDK4 (5 µM) was excited at 295 nm and the fluorescence was measured at 350 nm.  
 
The ATP molecule also binds rPDK4 at the same site as ADP and it was of interest to 
determine whether the binding of ATP to rPDK4 has similar effects on the basal 
fluorescence of this protein as ADP.  Figure 29A depicts a reduction in fluorescence of 
rPDK4 with increasing amounts of ATP.  The maximum quenching effect for ATP on 
Trp383 fluorescence was 31 % (Figure 29B) and this was similar to 38 % for ADP (Figure 
28B).  The percentage quenching values obtained in this current work (calculated using 
equation 3) were below those reported by Hiromasa and co workers (2006) which were 
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53 % for ATP and 48 % for ADP.  The Kd value for ATP was determined to be 17.4 µM 
when the data was fitted on the hyperbolic fit (Figure 29C).   
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Figure 29: Quenching of basal rPDK4 fluorescence at 350 nm by ATP. 
rPDK4 (5 µM) was excited at 295 nm and the fluorescence was measured at 350 nm.  
 
The PDK proteins require Mg 2+ for its activity (Tovar-Mendez et al., 2005).  In an event 
when MgCl2 was not included in the buffer, ADP or ATP did not cause any quenching of 
basal fluorescence spectra rPDK4.  Therefore, the observed quenching of fluorescence is 
due to specific binding of ATP or ADP by rPDK4.  
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4 Discussion 
 
This research work focused on studying the structure of rPDK4 and further elucidating 
the binding properties of ADP to rPDK4.  In order to achieve this aim, the study was 
divided into two sections.  The first section involved utilization of computational 
methods to model the three dimensional structure of rPDK4.  The modelled structure of 
rPDK4 was to study the hypothetical interaction between rPDK4 and ADP.  The second 
section involved biochemical characterisation of the purified rPDK4 protein.  This 
included size determination using size exclusion chromatography, SDS-PAGE and 
Western blot analysis, as well as kinase activity assays.  The biochemical interaction of 
rPDK4 with ADP was studied using fluorescence quenching analysis.   
 
4.1 Structural bioinformatics analysis of rPDK4 
 
Analysis of the interaction of rPDK4 and the ADP molecule bound at the active site of 
the modelled rPDK4 revealed that amino acids Asn247, Asp282, Ser301, Thr302, Phe318 and 
Gly319 potentially make hydrogen bond interactions with the ADP molecule (Figure 15B).  
As described previously, these amino acids and their interactions appear to be conserved 
in all known isomers of PDK (Figure 5).  This suggests that the binding mechanism of 
ADP is similar for all the isomers.  This may increase the difficulty in designing active 
site inhibitors that would selectively bind rPDK4 and not the other PDK isomers since 
PDK4 has emerged as a potential drug target for the treatment of diabetes.  Due to the 
conservation of the nucleotide binding domain of rPDK4 it is unlikely to be an ideal drug 
target, and specificity would be a major concern.   
 
 60 
The first possible area of interest is the DCA binding site.  Knoechel et al. (2006) studied 
the structure of human PDK2 in an attempt to find novel ligand binding sites that would 
be isoform specific.  Taking into account that DCA has been shown to inhibit PDK 
activity by hindering dissociation of the ADP molecule at the active site (Bao et al., 
2004).  Knoechel et al. (2006) undertook experiments to locate the DCA binding site.  
This site was successfully mapped (Figure 9).  However, residues which constitute this 
site were also found to be conserved in all PDK isomers.  Hence, it is unlikely that the 
DCA binding site will prove suitable as a drug target site for the development of 
inhibitors.   
 
PDK dimers are recruited to the PDC by binding to the inner lipoyl (L2) domain of the 
E2 (Liu et al., 1995).  The L2 binding site could be another possible binding site that 
could be targeted.  Tuganova et al. (2001) studied the interaction between the PDK 
isomers and L2 and showed that they display different binding affinities for L2 and this 
suggested that the L2 binding site in PDK could be different for each isomer.  The 
findings of Tuganova et al. (2001) lead to the solving of the structure of human PDK3 
complexed with L2 of PDC (Kato et al., 2005).  It was observed from the structure of the 
PDK3-L2 complex that the L2 binds to PDK both at the N-terminal and C-terminal 
domains.  The interactions between the N-terminal domain and L2 are mainly 
hydrophobic and electrostatic, and they are similar in all isomers of PDK based on 
sequence conservation.  The tail of the C-terminal domain interacts with L2 through 
hydrogen bonding and the hydrogen bond network between the tail of C-terminal domain 
and L2 seems to be unique for each isomer (Kato et al., 2005).  Furthermore, truncation 
of the C-terminal tail of PDKs abolishes the binding of L2 thus indicating that this region 
is crucial for L2 and PDK interaction (Kato et al., 2005).  The work of Kato et al. (2005) 
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indicates that the C-terminal tail region of PDK could be targeted for the design of PDK 
inhibitors that are isoform specific. 
 
Another PDK ligand binding site that could be studied is that of the E1 subunit of PDC.  
It may lead to identification of isoform specific inhibitors of PDK because PDK isoforms 
are known to display differences in kinetic parameters, regulation and phosphorylation of 
E1 subunit (Bowker-Kinley et al., 1998 and Kolobova et al., 2001).  It could also be 
worthy to target inactive PDK proteins as they may differ slightly in structure between 
isoforms.  This approach has been employed successfully in designing Gleevec, a specific 
c-Abl kinase inhibitor which bind the inactive form of c-Abl kinase (Nagar et al., 2003). 
 
Hence, while the initial assumption that the ATP binding site could possibly be a suitable 
target site for the development of inhibitors appears to be incorrect, there are at least two 
other sites that can be targeted in future work.   
 
4.2 The binding of ATP and ADP to rPDK4 
 
ATP and ADP have been reported to bind PDK proteins at the active site (Steussy et al., 
2001 and Knoechel et al., 2006).  ATP, together with Mg2+ ions, is required for PDK 
activity (Tovar-Mendez et al., 2002 and Tuganova et al., 2001) while ADP inhibits the 
activity of PDK proteins (Pratt and Roche, 1979).  To analyze the binding of ADP and 
ATP to rPDK4 proteins, fluorescence quenching was used.   
 
Initial fluorescence work focused on determining basal fluorescence of rPDK4 in the 
absence of ATP and ADP.  Excitation of tyrosine and tryptophan at 280 nm gives much 
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higher fluorescence intensity compared to a fluorescence intensity attained by exciting 
rPDK4 (tryptophan alone) at 295 nm (Figure 26).  The difference in fluorescence 
emission wavelength when rPDK4 is excited at 280 than 295 nm is attributed to tyrosine 
and solvent inaccessible tryptophan residues which fluoresce at 280 nm.  
 
Subsequently, rPDK4 was titrated with either ADP or ATP.  Both ADP and ATP 
quenched the intrinsic fluorescence of rPDK4.  The quenching of rPDK4 fluorescence by 
ADP and ATP was indicative of ADP and ATP binding to the active site.  This was 
further supported by the inability of both ADP and ATP to quench Trp395 fluorescence in 
the absence of Mg2+ ions.  The quenching of rPDK4 fluorescence by ADP and ATP also 
confirmed that Trp395 is sensitive to the binding of ADP and ATP to the rPDK4 
nucleotide binding site.  It could, therefore, be used to monitor the binding effects of 
ligands that target the nucleotide binding site.   
 
The percentage quenching of rPDK4 basal fluorescence by ADP and ATP is shown in 
Figure 28B and Figure 29B, respectively.  The maximum quenching effect of ATP and 
ADP are similar with values of 31 and 38 %, respectively.  The Hill analysis of ADP and 
ATP binding yielded the nH value 0.7 and 0.5, respectively.  The obtained nH value for 
both ADP and ATP is descriptive of cooperativity between the two binding sites.  In an 
event where the nH is less than 1 the cooperativity between the two sites is termed 
negative.  This means that binding of ligand to one active site reduces the affinity of 
rPDK4 for the second ligand.   
 
Hiromasa et al. (2006), when performing a similar experiment using human PDK2, 
obtained the nH value of 1 for ADP.  In this study, using PDK4 from rat, the nH value of 
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0.7 was obtained.  The nH value of 1 describes non cooperativity between the two ADP 
binding sites implying that the two binding sites are independent and non interacting.  
The difference in the nH value published by Hiromasa et al. (2006) and the one obtained 
in this study could be attributed to the use of different isomers of PDK which were from 
different sources.   
 
The Hill analysis of ATP obtained in this work was compared to that of Hiromasa et al. 
(2006).  It was observed that both nH value describe a negative cooperativity between the 
two ATP binding sites.  However, a nH value of 0.5 obtained in this work shows that the 
two ATP binding sites in rPDK4 have  stronger negative cooperativity than those in 
human PDK2 since they gave an nH value of 0.9 which is closer to 1.   
 
Taking into consideration that ATP activates PDK activity and PDK functions as a dimer, 
one would assume that the two binding sites of ATP exhibit positive cooperativity.  This 
would mean that the binding of ATP to one monomer of PDK would increase the affinity 
of the other monomer to bind an ATP molecule.  However, this seems to be untrue for the 
case of PDKs.  Consequently, the nH of 0.5 for ATP was unanticipated.   
 
The Kd value of 37 µM for ADP and 17.4 µM for ATP obtained in this study illustrates 
that rPDK4 has higher affinity for ATP than for ADP.  This result is consistent with 
published work of Hiromosa et al. (2006) and Bao et al. (2004).  It was anticipated for 
ATP to have a higher affinity than ADP, since ATP is required for the catalysis of PDK.  
The moderate affinity binding of ATP will also greatly favour the exchange of ADP for 
ATP molecule to prevent PDK inhibition by ADP.   
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In order to design inhibitors that would effectively inhibit rPDK4 one has to take into 
account the high binding affinity of ATP for PDK.  Drug leads need to have a greater 
affinity for nucleotide binding site on PDK and out compete ATP binding.  While it may 
be worthy to design drugs that target the active site, the candidates that target the 
pyruvate binding site may be a worthwhile investigation since they have been shown to 
work synergistically with ADP.  Pyruvate binding has been successfully mapped using 
DCA, a structural analog of pyruvate.  The binding of DCA or pyruvate is reported to 
induce conformational changes that prevent dissociation of ADP from the active site thus 
locking ADP in the active site of PDK (Bao et al., 2004).   
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4.3 Conclusions and future work 
 
Rat PDK4 has been successfully expressed and purified.  It was found to be active and 
binds both ATP and ADP.  This provides a good platform for future work in designing 
inhibitors that target the active site of this protein.  The structural analysis of the ADP 
binding site in this work has shown the disadvantages of designing drugs that target the 
active site.  It is important to design drug leads that would target other ligand binding 
sites such as the E1 and L2 binding sites on PDK.   
 
This work has also shown that Trp395 can successfully used to study the effects of ligands 
that bind to the PDK active site.  The presence of another tryptophan residue (Trp81) in 
PDKs (is located near the DCA binding site) could be exploited to studying the 
interaction between rPDK4 and DCA or other PDK inhibitors that target the DCA 
binding site using tryptophan fluorescence.  As yet, monitoring of the interaction of PDK 
and DCA using tryptophan fluorescence does not appear to have been investigated.   
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